Prescription Drugs

The Medicare Part D program provides an outpatient prescription drug benefit to more than 50 million older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone prescription drug plans (PDPs) to supplement traditional Medicare and Medicare Advantage prescription drug plans (MA-PDs) that include drug coverage and other Medicare-covered benefits. This brief analyzes Medicare Part D enrollment and costs in 2025 and trends over time, based on data from the Centers for Medicare & Medicaid Services (CMS).

This brief focuses on the stand-alone Medicare Part D prescription drug plan marketplace and its somewhat uncertain future, in light of recent trends in plan availability and the potential for another year of premium increases in 2026, in part depending on what the Trump administration decides to do with the temporary Part D premium stabilization demonstration. The brief explains why the stability of the PDP market matters, both for people in traditional Medicare who want prescription drug coverage but also for the viability of traditional Medicare as an option vis a vis Medicare Advantage.

These charts highlight data from a poll on Seniors and the Medicare Prescription Drug Benefit, conducted jointly by the Kaiser Family Foundation and the Harvard School of Public Health between November 9 and 19, 2006. It included a nationally representative sample of 718 seniors, including 275 who reported being enrolled…

The survey, which assessed seniors’ views of and experiences with the Medicare drug benefit, was conducted November 9-19 by the Kaiser Family Foundation and the Harvard School of Public Health. It included a nationally representative sample of 718 seniors, including 275 who reported being enrolled in a Medicare drug plan.…

This survey from NPR, the Kaiser Family Foundation, and the Harvard School of Public Health examines the public’s views of over-the-counter children’s cold and cough medications in the wake of recent concerns regarding their safety and effectiveness. The poll was conducted after an FDA advisory panel recommended that children under…

This document provides key findings from a USA Today/Kaiser/Harvard survey examining Americans’ views on, and experiences with, prescription drugs and the pharmaceutical industry, including drug costs, advertisements, safety issues, government regulation and medical research. Summary and Charts (.pdf)

This document includes the toplines from the joint USA Today/Kaiser/Harvard School of Public Health survey exploring Americans’ views on health care costs.Survey Toplines (.pdf)

This poll, the third in a series conducted jointly by USA Today and public opinion researchers at the Kaiser Family Foundation and the Harvard School of Public Health, by USA Today, the Kaiser Family Foundation and the Harvard School of Public Health finds Americans greatly value prescription drugs’ potential benefits…

This chartpack is part of a survey by the Kaiser Family Foundation and Harvard School of Public Health that examines public opinion on the Medicare prescription drug debate. The survey, a follow-up to a broader, more comprehensive survey released in June 2003 about the Medicare program and proposed changes, finds…

These toplines are part of a survey by the Kaiser Family Foundation and Harvard School of Public Health that examines public opinion on the Medicare prescription drug debate. The survey, a follow-up to a broader, more comprehensive survey released in June 2003 about the Medicare program and proposed changes, finds…